ConfirmMDx was designed to be used in patients where there is a suspicion of prostate cancer but, despite undergoing TRUS biopsy, have not been appropriately diagnosed (due to the random nature of the TRUS biopsy). This problem becomes further problematic by the fact that prostate cancer is often a disease that occurs in more than one area of the prostate.
Individuals presenting with risk factors, including abnormal DRE, elevated/rising prostate specific antigen (PSA), elevated/high risk biomarkers such as SelectMDx, in combination with one or multiple negative/atypical prostate biopsies may benefit from a ConfirmMDx test. By testing for the presence of hypermethylation (which is when certain molecules bind to areas of the genetic code (DNA) that have been shown to be precursors to initiating/promoting prostate cancer) of 3 biomarkers from your benign/atypical prostate tissue, your health care provider may be able to determine which area(s) of the prostate may be “hot spots” for prostate cancer, subsequently targeting these zone(s) of suspicion at the time of repeat
Below are several resources designed to help patients and their family better understand how ConfirmMDx is used in a clinical setting, including a video as well as downloadable brochures.